Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25121956)

  • 1. Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib.
    Pommier AJ; Shaw R; Spencer SK; Morgan SR; Hoff PM; Robertson JD; Barry ST; Jürgensmeier JM
    Br J Cancer; 2014 Oct; 111(8):1590-604. PubMed ID: 25121956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
    J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy.
    Jürgensmeier JM; Schmoll HJ; Robertson JD; Brooks L; Taboada M; Morgan SR; Wilson D; Hoff PM
    Br J Cancer; 2013 Apr; 108(6):1316-23. PubMed ID: 23449351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
    Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
    Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.
    Spencer SK; Pommier AJ; Morgan SR; Barry ST; Robertson JD; Hoff PM; Jürgensmeier JM
    Br J Cancer; 2013 Nov; 109(11):2765-73. PubMed ID: 24149180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
    Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
    Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of lactate dehydrogenase isoenzyme profile with outcome in patients with advanced colorectal cancer treated with chemotherapy and bevacizumab or cediranib: Retrospective analysis of the HORIZON I study.
    Bar J; Spencer S; Morgan S; Brooks L; Cunningham D; Robertson J; Jürgensmeier JM; Goss GD
    Clin Colorectal Cancer; 2014 Mar; 13(1):46-53. PubMed ID: 24355210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24.
    Bar J; Ding K; Zhao H; Han L; Laurie SA; Seymour L; Addison CL; Shepherd FA; Goss GD; Dimitroulakos J; Bradbury PA
    Clin Lung Cancer; 2015 Nov; 16(6):e189-201. PubMed ID: 26081815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of circulating vascular endothelial growth factor-A predict benefit from antiangiogenic cediranib in metastatic or recurrent cervical cancer patients.
    Zhou C; Taylor S; Tugwood J; Simpson K; Jayson GC; Symonds P; Paul J; Davidson S; Carty K; McCartney E; Rai D; Dive C; West C
    Br J Clin Pharmacol; 2019 Aug; 85(8):1781-1789. PubMed ID: 30980733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer.
    Pommier AJ; Farren M; Patel B; Wappett M; Michopoulos F; Smith NR; Kendrew J; Frith J; Huby R; Eberlein C; Campbell H; Womack C; Smith PD; Robertson J; Morgan S; Critchlow SE; Barry ST
    Cell Metab; 2016 Jan; 23(1):77-93. PubMed ID: 26626460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study.
    Kato T; Muro K; Yamaguchi K; Bando H; Hazama S; Amagai K; Baba H; Denda T; Shi X; Fukase K; Skamoto J; Mishima H
    Ann Oncol; 2012 Apr; 23(4):933-41. PubMed ID: 21828378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer.
    Cunningham D; Wong RP; D'Haens G; Douillard JY; Robertson J; Stone AM; Van Cutsem E;
    Br J Cancer; 2013 Feb; 108(3):493-502. PubMed ID: 23299530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
    Backen AC; Lopes A; Wasan H; Palmer DH; Duggan M; Cunningham D; Anthoney A; Corrie PG; Madhusudan S; Maraveyas A; Ross PJ; Waters JS; Steward WP; Rees C; McNamara MG; Beare S; Bridgewater JA; Dive C; Valle JW
    Br J Cancer; 2018 Jul; 119(1):27-35. PubMed ID: 29925934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.
    Martin P; Noonan S; Mullen MP; Scaife C; Tosetto M; Nolan B; Wynne K; Hyland J; Sheahan K; Elia G; O'Donoghue D; Fennelly D; O'Sullivan J
    BMC Cancer; 2014 Nov; 14():887. PubMed ID: 25428203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
    Lambrechts D; Thienpont B; Thuillier V; Sagaert X; Moisse M; Peuteman G; Pericay C; Folprecht G; Zalcberg J; Zilocchi C; Margherini E; Chiron M; Van Cutsem E
    Br J Cancer; 2015 Sep; 113(7):1027-34. PubMed ID: 26355232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.
    Gerstner ER; Ye X; Duda DG; Levine MA; Mikkelsen T; Kaley TJ; Olson JJ; Nabors BL; Ahluwalia MS; Wen PY; Jain RK; Batchelor TT; Grossman S
    Neuro Oncol; 2015 Oct; 17(10):1386-92. PubMed ID: 26008604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study.
    Mulders P; Hawkins R; Nathan P; de Jong I; Osanto S; Porfiri E; Protheroe A; van Herpen CM; Mookerjee B; Pike L; Jürgensmeier JM; Gore ME
    Eur J Cancer; 2012 Mar; 48(4):527-37. PubMed ID: 22285180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.